Sec Form 4 Filing - Abdul-Wahab Umari @ IDERA PHARMACEUTICALS, INC. - 2014-05-21

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Abdul-Wahab Umari
2. Issuer Name and Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC. [ IDRA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET
3. Date of Earliest Transaction (MM/DD/YY)
05/21/2014
(Street)
CAMBRIDGE, MA02139
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/21/2014 S 250,000 D $ 0 0 ( 2 ) I See Footnotes ( 1 ) ( 2 )
Common Stock 05/22/2014 S 250,000 D $ 0 0 ( 2 ) I See Footnotes ( 1 ) ( 2 )
Common Stock 05/23/2014 S 45,000 D $ 0 0 ( 2 ) I See Footnotes ( 1 ) ( 2 )
Common Stock 05/23/2014 X 575,758 A $ 0 0 ( 3 ) I See Footnotes ( 2 ) ( 3 )
Common Stock 05/23/2014 X 313,341 A $ 0 0 ( 4 ) I See Footnotes ( 2 ) ( 4 )
Common Stock 05/23/2014 X 110,901 A $ 0 0 ( 5 ) I See Footnotes ( 2 ) ( 5 )
Table II - Deriv ative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $ 0.79 05/23/2014 X 575,758 05/07/2013 06/01/2014 Common Stock 575,758 $ 0 0 I See Footnotes ( 2 ) ( 3 )
Warrants $ 0.79 05/23/2014 X 313,341 05/07/2013 06/01/2014 Common Stock 313,341 $ 0 0 I See Footnotes ( 2 ) ( 4 )
Warrants $ 0.79 05/23/2014 X 110,901 05/07/2013 06/01/2014 Common Stock 110,901 $ 0 0 I See Footnotes ( 2 ) ( 5 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Abdul-Wahab Umari
C/O IDERA PHARMACEUTICALS, INC.
167 SIDNEY STREET
CAMBRIDGE, MA02139
X
Signatures
/s/ Abdul-Wahab Umari 05/23/2014
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner.
( 2 )Abdul-Wahab Umari is a director of Pillar GP and serves as the representative of a Pillar I, Pillar II and Pillar GP on the Issuer's board of directors. Mr. Umari disclaims Section 16 beneficial ownership of the Pillar I Warrants, Pillar II Warrants and the Besancon Warrants (including in each case the common stock underlying such warrants) and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. Umari owns directly 67,304 shares of common stock of the Issuer.
( 3 )Warrants beneficially owned and exercised for shares of common stock by Pillar I, of which Pillar GP is the general partner (the "Pillar I Warrants").
( 4 )Warrants beneficially owned and exercised for shares of common stock by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner (the "Pillar II Warrants") of the Issuer.
( 5 )Warrants beneficially owned and exercised for shares of common stock by Participations Besancon, a fund advised by Pillar GP (the "Besancon Warrants").

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.